Sirpa Leppä

Sirpa Leppä

UNVERIFIED PROFILE

Are you Sirpa Leppä?   Register this Author

Register author
Sirpa Leppä

Sirpa Leppä

Publications by authors named "Sirpa Leppä"

Are you Sirpa Leppä?   Register this Author

60Publications

1367Reads

9Profile Views

Clinical features and outcome of the patients with sinonasal tract diffuse large B-cell lymphoma in the pre-rituximab and rituximab eras.

Eur J Haematol 2019 Jun 9;102(6):457-464. Epub 2019 Apr 9.

Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and Research Program in Applied Tumor Genomics, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ejh.13225
Publisher Site
http://dx.doi.org/10.1111/ejh.13225DOI Listing
June 2019

Distinct subtypes of diffuse large B-cell lymphoma defined by hypermutated genes.

Leukemia 2019 Jun 11. Epub 2019 Jun 11.

Research Programs Unit, Research Program in Systems Oncology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41375-019-0509-6
Publisher Site
http://dx.doi.org/10.1038/s41375-019-0509-6DOI Listing
June 2019

Identifying differentially methylated sites in samples with varying tumor purity.

Bioinformatics 2018 09;34(18):3078-3085

Research Programs Unit, Genome-Scale Biology, Medicum and Department of Biochemistry and Developmental Biology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/bioinformatics/bty310DOI Listing
September 2018

HIV infection and cancer.

Duodecim 2016;132(18):1647-52

View Article

Download full-text PDF

Source
January 2018

Clinical significance of gene defects in B-cell lymphomas.

Duodecim 2017 ;133(9):839-46

View Article

Download full-text PDF

Source
January 2018

Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma.

J Clin Oncol 2017 Dec 4;35(35):3898-3905. Epub 2017 Oct 4.

Martin Dreyling, Ludwig Maximilians University of Munich, Munich; Georg Lenz, University Hospital Münster, Münster; Marius Giurescu, Karl Köchert, Henrik Seidel, and Florian Hiemeyer, Bayer AG, Berlin, Germany; Armando Santoro, Humanitas Clinical and Research Center, Rozzano; Pier Luigi Zinzani, University of Bologna, Bologna, Italy; Luigina Mollica, Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; George A. Follows, Addenbrooke's Hospital, Cambridge, United Kingdom; Won Seog Kim, Samsung Medical Center, Seoul, South Korea; Arnon Nagler, Tel Aviv University, Tel HaShomer, Israel; Panayiotis Panayiotidis, National and Kapodistrian University of Athens, Athens, Greece; Judit Demeter, Semmelweis University, Budapest, Hungary; Muhit Özcan, Ankara University School of Medicine, Ankara, Turkey; Marina Kosinova, Kemerovo Regional Clinical Hospital, Kemerovo, Russian Federation; Krimo Bouabdallah, University Hospital of Bordeaux, Pessac; Franck Morschhauser, Hôpital Claude Huriez, Lille, France; Don A. Stevens, Norton Cancer Institute, Louisville, KY; David Trevarthen, Comprehensive Cancer Care and Research Institute of Colorado, Englewood, CO; and Lisa Cupit, Li Liu, Carol Peña, Shuxin Yin, Jose Garcia-Vargas, and Barrett H. Childs, Bayer HealthCare Pharmaceuticals, Whippany, NJ.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.4648DOI Listing
December 2017

Clinical findings in 25 patients with sinonasal or nasopharyngeal extramedullary plasmacytoma in a four-decade single-centre series.

Acta Otolaryngol 2017 Sep 24;137(9):975-980. Epub 2017 May 24.

a Department of Otorhinolaryngology - Head and Neck Surgery , University of Helsinki and Helsinki University Hospital , Helsinki , Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00016489.2017.1325514DOI Listing
September 2017

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.

J Clin Oncol 2017 Feb 28;35(5):544-551. Epub 2016 Dec 28.

Gustaaf W. van Imhoff, University Medical Center, University of Groningen; Bronno van der Holt, University Medical Center, Rotterdam; Anton Hagenbeek, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands; Andrew McMillan, Nottingham University Hospital, Nottingham; John Radford and Kirit M. Ardeshna, Christie Hospital NHS Trust, Manchester; Andrew Davies, University of Southampton, Southampton, United Kingdom; Matthew J. Matasar, Memorial Sloan Kettering Cancer Center, New York, NY; Kazimierz Kuliczkowski, Wroclaw Medical University, Wroclaw, Poland; WonSeog Kim, Sungkyunkwan University School of Medicine, Seoul, Korea; Xiaonan Hong, Fudan University, Shanghai, China; Jette Soenderskov Goerloev, Rigshospitalet; Steen Lisby, Genmab A/S, Copenhagen, Denmark; María Dolores Caballero Barrigón, Hospital Universitario de Salamanca, Salamanca, Spain; Michinori Ogura, Nagoya Daini Red Cross Hospital, Nagoya; Michinori Ogura, Tokai Central Hospital, Kakamigahara, Japan; Sirpa Leppä, Helsinki University Central Hospital Cancer Center, Helsinki, Finland; and Michael Fennessy and Qiming Liao, Novartis AG, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.0198DOI Listing
February 2017

Clinical findings of extranodal SNT lymphoid malignancies in a four-decade single-centre series.

Eur Arch Otorhinolaryngol 2016 Nov 24;273(11):3839-3845. Epub 2016 Mar 24.

Department of Otorhinolaryngology-Head and Neck Surgery, Helsinki University Hospital, University of Helsinki, P.O. Box 263, FI-00029 HUH, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00405-016-3992-7DOI Listing
November 2016

FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance disorders.

Neurology 2016 Nov 28;87(22):2290-2299. Epub 2016 Oct 28.

From the Research Programs Unit, Molecular Neurology (J.M.L., S.F., H.L., M.A., P.I.), Faculty of Medicine/Clinicum, Oncology (P.O.), and Finland Genome Scale Biology Program (S.L.), University of Helsinki, Finland; Mitochondrial Medicine Group (E.B., C.V., M.Z.), Medical Research Council Mitochondrial Biology Unit, Cambridge, UK; Center for Physiology and Pathophysiology (O.R.B., R.J.W.), Institute of Vegetative Physiology, University of Köln, Germany; Transplantation and Liver Surgery Clinic (H.I., K.H.), Department of Oncology (P.O., S.L.), and Heart and Lung Center, Department of Cardiology (T.H.), Helsinki University Hospital; School of Medicine (M.H., J.J., R.L.), University of Tampere; Anaesthesiology, Intensive Care and Pain Medicine (R.M.), Clinical Neurosciences, Neurology (H.L., M.A., A.S.), and Child Neurology, Children's Hospital (P.I.), University of Helsinki and Helsinki University Hospital, Finland; Dyslipidemia Center (G.M.), Cardiotoracovascular Department, Niguarda Hospital, Milan, Italy; PEDEGO Research Unit (J.U.) and Biocenter Oulu (J.U.), University of Oulu; Finnish Clinical Biobank Tampere (R.L.), Tampere University Hospital, Finland; Nijmegen Centre for Mitochondrial Disorders (J.S.), Radboud University Medical Centre, Nijmegen, the Netherlands; Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD) (R.J.W.), Köln; Center for Molecular Medicine Cologne (R.J.W.), CMMC, University of Köln, Germany; Faculty of Life and Environmental Sciences (K.N.), University of Tsukuba, Japan; and Medical Research Center Oulu (J.U.), Oulu University Hospital and University of Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000003374DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5270510PMC
November 2016

Allogeneic Haematopoietic Stem Cell Transplantation for Patients with Cutaneous T-cell Lymphoma.

Acta Derm Venereol 2016 08;96(6):816-7

Department of Dermatology, Center of Inflammation, Skin and Allergy Hospital, FIN-00250 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-2362DOI Listing
August 2016

Risk Factors and Outcomes for Patients With Follicular Lymphoma Who Had Histologic Transformation After Response to First-Line Immunochemotherapy in the PRIMA Trial.

J Clin Oncol 2016 08 13;34(22):2575-82. Epub 2016 Jun 13.

Clémentine Sarkozy and Gilles Salles, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Service d'Hématologie, Pierre Bénite and Université Claude Bernard, Faculté de Médecine Lyon-Sud Charles Mérieux Pierre Bénite; Luc Xerri, Aix-Marseille University and Institut Paoli-Calmettes, Marseille; Pierre Feugier, Centre Hospitalier Universitaire de Nancy and INSERM 954 Université de Lorraine, Nancy; Pauline Brice, Hôpital Saint Louis APHP and Université Paris VII; Danielle Canioni, Assistance Publique Hôpitaux de Paris (APHP) Hôpital Universitaire Necker-Enfants Malades; Richard Delarue, APHP Hôpital Universitaire Necker-Enfants Malades and Descartes-Sorbonne Paris Cité University, Paris; Pierre Soubeyran, Institut Bergonié and Université Victor Segalen Bordeaux, Bordeaux; Christiane Mounier, Institut de Cancérologie Lucien Neuwirth, Saint Priest; Jehan Dupuis, Henri Mondor University Hospital, Créteil; Hervé Tilly, Université de Rouen, Rouen, France; Marek Trneny, Charles University General Hospital, Prague, Czech Republic; Nick Wickham, University of Adelaide, Adelaide; Marlton Paula, Princess Alexandra Hospital, University of Queensland School of Medicine, Brisbane; John Seymour, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia; Sirpa Leppa, Helsinki University Hospital Cancer Center and University of Helsinki, Helsinki, Finland; Maria Gomes Da Silva, Instituto Português de Oncologia de Lisboa, Lisbon, Portugal; Fritz Offner, Gent University, Gent; Pierre Zachee, ZNA Stuivenberg, Antwerp, Belgium; and Dolores Caballero, Universitario de Salamanca, Salamanca, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7163DOI Listing
August 2016

Randomized, Double-Blind, Phase III Trial of Enzastaurin Versus Placebo in Patients Achieving Remission After First-Line Therapy for High-Risk Diffuse Large B-Cell Lymphoma.

J Clin Oncol 2016 07 23;34(21):2484-92. Epub 2016 May 23.

Michael Crump, Princess Margaret Cancer Centre, Toronto, Ontario; Kerry J. Savage, British Columbia Cancer Agency, Vancouver, British Columbia, Canada; Sirpa Leppä, Helsinki University Hospital Cancer Center, Helsinki, Finland; Luis Fayad, The University of Texas MD Anderson Cancer Center, Houston, TX; Frederick Schnell, Central Georgia Cancer Care, Macon, GA; Robert Rifkin, US Oncology Research Network and Rocky Mountain Cancer Centers, Denver, CO; Lauren Pinter-Brown, University of California at Los Angeles, Santa Monica, CA; Sonali Smith, University of Chicago, Chicago, IL; Eric D. Hsi, Cleveland Clinic, Cleveland, OH; Tuan Nguyen, Peipei Shi, Marjo Hahka-Kemppinen, Don Thornton, and Boris Lin, Eli Lilly and Company, Indianapolis, IN; Brad Kahl, University of Wisconsin, Madison, WI; Thomas Habermann, Mayo Clinic Cancer Research Consortium, Rochester, NY; Je Jung Lee, Chonnam National University Hwasun Hospital, Gwangju, South Korea; Alice Di Rocco, Sapienza University, Rome, Italy; Michinori Ogura, Tokai Central Hospital, Kakamigahara; Kensei Tobinai, National Cancer Center Hospital, Tokyo, Japan; Hans Hagberg, Akademiska Sjukhuset, Onkologkliniken, Uppsala, Sweden; Andreas Mackensen, University of Erlangen, Erlangen; Norbert Schmitz, Asklepios Klinik St Georg, Hamburg, Germany; Fritz Offner, University of Gent, Gent, Belgium; and Su-Peng Yeh, China Medical University Hospital, Taichung, Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.65.7171DOI Listing
July 2016

Total peroxiredoxin expression is associated with survival in patients with follicular lymphoma.

Virchows Arch 2016 May 16;468(5):623-30. Epub 2016 Mar 16.

Department of Oncology and Radiotherapy, University of Oulu and Medical Research Center, Oulu University Hospital, P.O. Box 22, 90029, Oulu, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00428-016-1920-2DOI Listing
May 2016

Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing.

Br J Haematol 2015 Aug 25;170(3):428-31. Epub 2015 Feb 25.

Department of Medical Genetics, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13295DOI Listing
August 2015

Combining MYC, BCL2 and TP53 gene and protein expression alterations improves risk stratification in diffuse large B-cell lymphoma.

Leuk Lymphoma 2015 Jun 19;56(6):1742-9. Epub 2014 Nov 19.

Department of Immunology, Institute for Cancer Research, Oslo University Hospital , Norway.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2014.970550DOI Listing
June 2015

Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial.

Haematologica 2015 Feb 7;100(2):238-45. Epub 2014 Nov 7.

Department of Oncology, Helsinki University Central Hospital Cancer Center, Finland Genome Scale Biology Program, University of Helsinki, Finland

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2014.113472DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803141PMC
February 2015

[Prognostic factors and treatment of diffuse large cell B-cell lymphoma].

Duodecim 2014 ;130(21):2181-9

HYKS syöpäkeskus ja Helsingin yliopisto.

View Article

Download full-text PDF

Source
January 2015

Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP.

Leuk Res 2013 Apr 24;37(4):386-91. Epub 2013 Jan 24.

Division of Hematology and Oncology, Rhode Island Hospital/The Miriam Hospital, Providence, RI 02906, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2013.01.002DOI Listing
April 2013

The Hans algorithm is not prognostic in patients with diffuse large B-cell lymphoma treated with R-CHOP.

Leuk Res 2012 Apr 24;36(4):413-7. Epub 2012 Jan 24.

Division of Hematology and Oncology, The Warren Alpert Medical School of Brown University, The Miriam Hospital, Providence, RI 02906, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.leukres.2011.12.012DOI Listing
April 2012

Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B-cell lymphoma.

Oncol Rep 2011 Apr 10;25(4):1183-90. Epub 2011 Feb 10.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/or.2011.1179DOI Listing
April 2011

Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy.

Eur J Haematol 2011 Feb 22;86(2):124-8. Epub 2010 Dec 22.

Department of Oncology, Helsinki University Central Hospital, Helsinki Genome-Scale Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2010.01541.xDOI Listing
February 2011

CD40 is a potential marker of favorable prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Leuk Lymphoma 2010 Sep;51(9):1643-8

Department of Oncology, Institution of Clinical Sciences, Lund University and Lund University Hospital, Lund, Sweden.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.492537DOI Listing
September 2010

Prognostic impact of CD31-positive microvessel density in follicular lymphoma patients treated with immunochemotherapy.

Eur J Cancer 2010 Sep 12;46(13):2506-12. Epub 2010 Jul 12.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2010.06.014DOI Listing
September 2010

Prognostic impact of protein kinase C beta II expression in R-CHOP-treated diffuse large B-cell lymphoma patients.

Mod Pathol 2010 May 26;23(5):686-93. Epub 2010 Feb 26.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2010.43DOI Listing
May 2010

Transcription factor AP-1 promotes growth and radioresistance in prostate cancer cells.

Int J Oncol 2009 Nov;35(5):1175-82

Molecular Cancer Biology Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo_00000434DOI Listing
November 2009

Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP.

Mod Pathol 2009 Aug 15;22(8):1094-101. Epub 2009 May 15.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2009.73DOI Listing
August 2009

Bcl-2 but not FOXP1, is an adverse risk factor in immunochemotherapy-treated non-germinal center diffuse large B-cell lymphomas.

Eur J Haematol 2009 May 9;82(5):364-72. Epub 2009 Jan 9.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2009.01222.xDOI Listing
May 2009

[Is lymphoma curable with antibody therapy?].

Duodecim 2009 ;125(3):267-73

HUS, Syöpätautien klinikka, PL 180, 00029 HUS.

View Article

Download full-text PDF

Source
April 2009

Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.

Blood 2008 May 28;111(9):4664-7. Epub 2008 Feb 28.

Department of Oncology, Helsinki University Central Hospital, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2007-11-125823DOI Listing
May 2008

Hydrocortisone and indomethacin negatively modulate EGF-R signaling in human fetal intestine.

Pediatr Res 2007 Nov;62(5):570-5

Molecular Cancer Biology Program, University of Helsinki, FIN-00014, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1203/PDR.0b013e318155ac3bDOI Listing
November 2007

EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways.

J Cell Physiol 2007 Aug;212(2):489-97

Molecular Cancer Biology Research Program, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.21041DOI Listing
August 2007

Mitogen activated protein kinase-dependent activation of c-Jun and c-Fos is required for neuronal differentiation but not for growth and stress response in PC12 cells.

J Cell Physiol 2007 Feb;210(2):538-48

Department of Oncology, Helsinki University Central Hospital, HUCH, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcp.20907DOI Listing
February 2007

AP-1 regulates alpha2beta1 integrin expression by ERK-dependent signals during megakaryocytic differentiation of K562 cells.

Exp Cell Res 2005 Mar 18;304(1):175-86. Epub 2004 Nov 18.

Molecular Cancer Biology Research Program, Biomedicum Helsinki and Haartman Institute, P.O. Box 63, FIN-00014 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.yexcr.2004.10.017DOI Listing
March 2005

A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma.

Clin Cancer Res 2004 Feb;10(3):1057-63

Department of Oncology, Helsinki University Central Hospital, PO Box 180, FIN-00029 Helsinki, Finland.

View Article

Download full-text PDF

Source
February 2004

Pretreatment serum syndecan-1 levels and outcome in small cell lung cancer patients treated with platinum-based chemotherapy.

Lung Cancer 2003 Aug;41(2):171-7

Department of Oncology, Helsinki University Central Hospital, P.O. Box 180, FIN-00029, Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0169-5002(03)00196-xDOI Listing
August 2003

Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.

Cancer Res 2002 Sep;62(18):5210-7

Department of Oncology, Helsinki University Central Hospital, Haartmaninkatu 4, PO Box 180, FIN-00029 Helsinki.

View Article

Download full-text PDF

Source
September 2002

Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells.

J Biol Chem 2002 May 7;277(18):15992-6001. Epub 2002 Mar 7.

Molecular Cancer Biology Research Program, Biomedicum Helsinki and Haartman Institute, University of Helsinki, P. O. Box 63, FIN-00014 Helsinki, Finland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M107340200DOI Listing
May 2002